Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation
ShareCopied to clipboardAdalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation is a book. It was written by Matt Stevenson and published by NIHR Journals Library in 2016.
Key facts
- author: Matt Stevenson
- publication date: 2016
- book publisher: NIHR Journals Library
- book series: Health technology assessment
- book subjects: Clinical trials
See more factsExtract data
Download datasets about Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation:
Dataset of books series that contain Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation:
Dataset of book subjects that contain Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation:
"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only : systematic review and economic evaluation" is one of the books by Matt Stevenson, books by NIHR Journals Library and 2,617,384 books in our database.
This dashboard is based on data from: The British Library.
This content is available under the CC BY 4.0 license.